ALS Association Grants

The ALS Association’s scientific research program, TREAT ALS (Translational Research Advancing Therapy for ALS), encourages translational research to bring new treatments to patients with Amyotrophic Lateral Sclerosis. Currently, there is only one FDA-approved drug for ALS, Riluzole, which has a modest effect on patient survival.

Grants will be awarded for:

  • Clinical Research Pilot Studies, to obtain preliminary data that will support applications to the NINDS for larger clinical trials of an intervention to treat or prevent ALS. These awards total $300,000 ($150,000/year for two years).
  • Clinical Management, aimed at improving care for individuals with ALS, with a focus on clinical, psychological, and/or social management of the disease. These awards total $200,000 ($100,000/year for two years).            

This is an open competition. There is no limitation on the number of applicants from the same institution, and an institutional nomination is not required. Applicants must submit a preliminary brief study outline by May 28, 2012. Requests for full applications will be sent out by June 29, 2012. Full proposals are due by September 10, 2012.

 

For further information and copies of the study outline form, contact Dr. Paul A. Spengler, Director of Foundation Relations, at 276-3955 or pspengler@admin.rochester.edu. For more information about the ALS grants, please click here.

 

NIH Funding Acknowledgement ** Important ** All publications resulting from the utilization of CTSI resources are required to credit the CTSI grant by including the NIH FUNDING ACKNOWLEDGEMENT and must comply with the NIH Public Access Policy.